Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

J. E. Kurtz,E. Pujade-Lauraine, A. Oaknin, L. Belin, I. Tsibulak, D. Cibula,I. B. Vergote, O. S. Rosengarten, M. J. Rodrigues,N. De Gregorio, J. Martinez-Garcia,P. Pautier, M. A. Mouret Reynier, F. Selle, V. D'Hondt,F. Joly Lobbedez, E. Bultot Boissier,A. Floquet, P-E. Heudel, F. Heitz

ANNALS OF ONCOLOGY（2022）

引用 0|浏览6

暂无评分

摘要

Standard Cx for PSROC (> 6 months after last platinum dose) includes carboplatin plus pegylated liposomal doxorubicin (CbD) or gemcitabine (CbG) or paclitaxel (CbP) with or without bev. ATALANTE/ENGOT-ov29 (NCT02891824) is the first Phase III trial to evaluate Atz with Cx and bev for pts with PSROC.

查看译文

关键词

ovarian cancer,epithelial ovarian cancer,lba30 phase iii atalante/ov29,chemotherapy,atalante/ov29 trial,platinum-based,platinum-sensitive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要